Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease

NCT01624376 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Fistulizing Crohn's Disease

Interventions

DRUG: DLX105
DRUG: Placebo

Sponsor

Delenex Therapeutics AG